|Bid||79.30 x 1000|
|Ask||84.00 x 800|
|Day's Range||77.66 - 87.80|
|52 Week Range||76.34 - 153.41|
|Beta (5Y Monthly)||1.47|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 28, 2022 - Mar 04, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||226.00|
Subscribe to Yahoo Finance Plus to view Fair Value for RETALearn more
Investors need to pay close attention to Reata (RETA) stock based on the movements in the options market lately.
PLANO, Texas, November 19, 2021--Reata Pharmaceuticals, Inc. (Nasdaq: RETA), ("Reata," the "Company," "our," "us," or "we"), a clinical-stage biopharmaceutical company, today announced the U.S. Food and Drug Administration ("FDA") has granted Fast Track Designation for omaveloxolone for the treatment of Friedreich’s ataxia.
Reata (RETA) beats estimates for earnings and sales. An advisory committee meeting is scheduled on Dec 8 to discuss bardoxolone NDA.